Chromium Picolinate Important for Insulin Resistance and Chronic
Disease
Boston
MA, 1 April 2003
Leading
Experts Convene at Chromium Research Summit Sponsored by the Council
for the Advancement of Diabetes Research and Education (CADRE)
Leading
scientific researchers presented the latest epidemiological and
clinical data on the role of chromium picolinate supplementation
in chronic disease at the Council for the Advancement of Diabetes
Research and Education (CADRE) Research Summit: Chromium in Health
and Disease. Recent research suggests that chromium enhances insulin
action which may help lower some risk factors for diseases associated
with insulin resistance, such as obesity, cardiovascular disease,
type 2 diabetes, Polycystic Ovarian Syndrome (PCOS) and atypical
depression.
Insulin
resistance is a condition associated with obesity and is also strongly
related to hypertension, lipid disorders and cardiovascular disease.
"Prior human studies have suggested that chromium picolinate decreases
insulin levels and improves blood sugar metabolism in both obese
people and people with type 2 diabetes," stated William T. Cefalu,
MD, Associate Professor of Medicine at the University of Vermont
College of Medicine and co-chair of the CADRE Summit. "This summit
is important because not only will leading experts present relevant
data regarding clinical observations with this nutrient, but precise
studies assessing the mechanism of action will be presented," added
Cefalu.
Chromium
is an essential mineral that potentiates insulin, a hormone that
influences carbohydrate, lipid and protein metabolism. "There is
a widespread tendency toward increased consumption of highly processed
foods such as refined sugar which is not only low in chromium, but
also stimulates chromium losses," states Richard Anderson, PhD,
US Department of Agriculture, Beltsville Human Nutrition Research
Center. "Essentially all the studies using chromium picolinate supplementation
for impaired glucose intolerance and diabetes showed a positive
effect," added Anderson.
The
Institute of Medicine (IOM) reviewed the scientific literature on
chromium picolinate and did not find any basis to set an Upper Limit
(UL), meaning that there were no substantive concerns about safety
of chromium at any of the levels used in relevant studies. "This
review included human studies of supplemental chromium (as chromium
picolinate) up to 1000 micrograms (mcg) per day and there were no
observed adverse effects from intake of chromium, hence chromium
picolinate is safe," commented John Hathcock, PhD, vice president,
scientific and international affairs of the Council for Responsible
Nutrition (CRN).
About
the Council for the Advancement of Diabetes Research and Education
The
Council for the Advancement of Diabetes Research and Education (CADRE)
is a not-for-profit organization committed to reducing the devastating
complications of both type 1 and type 2 diabetes through achievement
of tight metabolic control. To achieve this goal, CADRE provides
health care professionals with scientific information and educational
programs that support, highlight, and promote practical guidelines
for patient education and management as well as cutting-edge research
in diabetes pathophysiology and treatment.
CADRE
programs are funded by educational grants from Aventis Pharmaceuticals,
Pfizer Inc, and Nutrition 21. For more information about CADRE's
mission and programs, visit www.cadre-diabetes.org.
Source
Council
for the Advancement of Diabetes Research and Education.
|